ストックスクリーナーアプリを入手
1.52
8.57%
0.12
アフターアワーズ：
1.56
0.04
+2.63%
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Price to book forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to sales forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to earnings forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Actuate Therapeutics (ACTU) Declines Sharply – Key Support Tested at $1.73Double Top - dars.gov.et
Actuate Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACTU) - TradingView
ACTU Forecast — Price Target — Prediction for 2027 - TradingView
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock ReactionFinancial Health Score - newsline.com
Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
ACTU Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Advances PipelineEarnings Volatility Report - newsline.com
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained - TipRanks
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion - Investing.com
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial - Investing.com
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit - Quiver Quantitative
Experimental cancer drug elraglusib joins landmark pediatric neuroblastoma trial - Stock Titan
Actuate Therapeutics (ACTU) Surges 6.59% as Biotech Momentum Builds Above Key SupportSystematic Flow - newsline.com
Elraglusib shows significant survival benefits in metastatic pancreatic cancer combined with standard chemo. - Pluang
Actuate presents elraglusib trial data at ASCO meeting By Investing.com - Investing.com South Africa
Actuate presents elraglusib trial data at ASCO meeting - Investing.com
Actuate Therapeutics Reports Positive Survival Outcomes for Elraglusib in Combination with Standard Chemotherapies for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO 2026 - Quiver Quantitative
Actuate Therapeutics Announces ASCO Poster Presentations - GlobeNewswire
Actuate Therapeutics, Inc. Presents Clinical And Biomarker Data For Elraglusib In First-Line Metastatic Pancreatic Cancer At ASCO - marketscreener.com
Actuate Therapeutics (ACTU) Declines 2.88% as Stock Nears Key Support ZoneEarnings Beat Stocks - The Legal Advocate
Actuate Therapeutics (ACTU) Holds Near Support Amid Low VolatilityVolume Spike Alerts - The Legal Advocate
Actuate Therapeutics (ACTU) Drops 4.09% as Shares Test Critical $2.00 Support LevelFlat Correction - newsline.com
ACTUActuate Therapeutics Inc Stock Price and Quote - Finviz
ACTU Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseGuidance vs Actual - Newser
Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India
Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks
Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal
Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
ACTU Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co. - Moomoo
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):